Inflexion, a leading European mid-market private equity firm, is pleased to announce that L'Oréal Groupe has agreed to acquire a majority shareholding in premium British skincare brand, Medik8. The partnership with L'Oréal will allow Medik8 to deepen its presence in existing markets and expand globally. As part of the transaction, Inflexion will retain a minority shareholding in Medik8.
Founded in 2009 by British scientist Elliot Isaacs, Medik8 is a premium clinical skincare brand, offering high-quality active skincare products which deliver clinical results without compromising on experience. Best known for its iconic Crystal Retinal serum and its trademark CSA Philosophy®, Vitamin C and Sunscreen by Day, Vitamin A by night, Medik8 formulates and manufactures its products in-house in its UK Innovation Centre.
During Inflexion’s four-year investment, Medik8 has achieved significant global growth, tripling both its headcount and sales, expanding across Europe, Australia, and notably strengthening its US presence with US revenue share increasing sevenfold. With Inflexion’s backing, the brand has enhanced its digital capabilities, driving a six-times increase in direct-to-consumer sales, and opened a 100,000 sq. ft. Innovation Centre in the first year of the partnership, tripling R&D and operational capacity. Contributing to the successful launch of several award-winning products, in that time frame, including Liquid Peptides Advanced MP. Significant investment in organisational design saw the appointment of a Chair, CEO, CPO and CMO and new roles in digital, data, innovation and sustainability with Medik8 achieving B Corp™ certification in 2024, underscoring its commitment to sustainability.
